RCKT Rocket Pharmaceuticals
Focus: FDA PDUFA for KRESLADI™ (LAD-I) on March 28, 2026 – gene therapy, rare pediatric disease.
Copy and paste this URL into your WordPress site to embed
Copy and paste this code into your site to embed